Best Life Insurance for Kidney Disease

Research Snapshot

• Topic: Best life insurance carriers for consumers with chronic kidney disease or a history of impaired kidney function.
• Target buyer: A U.S. consumer with chronic kidney disease or impaired kidney function who understands that underwriting may depend on diagnosis, stage or severity, kidney-function measurements, cause, treatment, progression, blood pressure, diabetes, and overall health.
• Platforms included (7): openai, anthropic, deepseek, grok, perplexity, kimi, google.
• Research date: 2026-09-22.
• Unique entities named: 23.
• Qualifying entities: 10.
• Eligibility rule: An entity qualified only if it was named by at least two platforms during ranking discovery.
• Ranking unit: Life insurance carrier.
• Geography: United States.

The Consensus Ranking

Questions This Section Answers

• What are the best life insurance carriers for kidney disease in 2026?
• Which carrier do AI platforms most consistently recommend for applicants with chronic kidney disease?

The table below is the study's final ranking. Order is based on platform mentions, then average listed rank, then best listed rank. Platform mentions count only platforms that named the entity during ranking discovery; all 7 platforms evaluated fit, but not every platform named every carrier.

Which Option Is Best for Which Version of the Buyer Need?

Questions This Section Answers

• Which life insurance carrier should a buyer with Stage 4–5 CKD or dialysis choose if guaranteed acceptance matters most?
• Is Mutual of Omaha or Protective better for kidney disease when the applicant has stable, well-documented Stage 2 CKD?
• Which carrier for kidney disease has the lowest published starting cost, and what fees apply?

Buyer fit depends less on the carrier's overall reputation than on the applicant's CKD stage, documentation quality, and coverage goal. The table below maps common buyer situations to the ranked carriers.

1. Mutual of Omaha

Questions This Section Answers

• Is Mutual of Omaha worth it for life insurance with kidney disease, and what are its main drawbacks?
• Does Mutual of Omaha's Living Promise pay full benefits immediately for someone with chronic kidney disease?

Verdict. Mutual of Omaha is the consensus leader for this use case, named by all 7 platforms. It is a good fit for a consumer with chronic kidney disease who prioritizes acceptance and modest permanent coverage, especially when conventional underwriting may result in a decline ^[1]. It is a weaker fit when the buyer needs substantial coverage, wants the lowest possible premium, or may qualify for medically underwritten term or simplified-issue coverage with better economics.

Why it ranked here. Mutual of Omaha was the only carrier named by every platform, and it earned a best position of 1 from deepseek. Its Living Promise Whole Life product is offered in simplified-issue and guaranteed-issue versions with Level Benefit and Graded Benefit options ^[2]. The guaranteed whole life product advertises no medical exam, generally for ages 45–85, with coverage of $2,000–$25,000 ^[3]. Independent analysis identifies the company as offering "the best guaranteed issue life insurance option for people on dialysis or with advanced kidney disease" ^[4].

Best suited for. Applicants with advanced, unstable, or poorly documented kidney disease who need final-expense or small permanent coverage; applicants within the product age limits who want guaranteed-issue whole life without medical underwriting; and applicants with milder or stable kidney impairment who should first test simplified-issue or fully underwritten options.

Main strengths for the use case. Guaranteed-issue whole life can remain available when CKD or dialysis makes conventional underwriting difficult ^[1]. Living Promise creates a possible middle path between guaranteed issue and fully underwritten insurance for applicants with manageable health histories. The company holds an A+ (Superior) financial strength rating from AM Best and scored 707/1000 in J.D. Power's 2025 U.S. Life Insurance Study, ranking first among 23 insurers ^[5]. A critical illness rider covers kidney failure as a named eligible condition, though rider availability varies by state ^[6]. .

2. Protective

Questions This Section Answers

• Is Protective a good choice for life insurance with Stage 1–3 kidney disease, and what underwriting limits apply?
• Does Protective offer coverage for dialysis patients or only for early-stage CKD?

Verdict. Protective is a potentially viable option for a consumer with mild, stable chronic kidney disease, but it is not clearly a best fit based on public information. Kidney disease or a kidney disorder can make an applicant ineligible for Protective's accelerated-underwriting path, so applicants should expect traditional underwriting, possible medical records review, and potentially a medical exam ^[7].

Why it ranked here. Protective earned a best position of 1 from grok and perplexity, and an average listed position of 2.60 — the second-best average in the study. Independent review states Protective is one of the best insurers for stages 1–3 kidney disease with competitive rates for kidney conditions ^[8]. Google's evidence bundle notes Protective is recognized as a leading option for individuals with chronic kidney disease, frequently willing to offer coverage via table ratings (typically Table 4 to 10) for stable cases ^[9].

Best suited for. Applicants with stable, well-documented kidney impairment who are willing to undergo full medical underwriting; applicants seeking level-premium term coverage, potentially for 10 to 40 years; and applicants who value a possible conversion option to permanent coverage without new medical underwriting, subject to policy terms.

Main strengths for the use case. Protective Classic Choice term offers 10-, 15-, 20-, 25-, 30-, 35-, and 40-year terms, with consumer materials stating coverage amounts from $100,000 to $50,000,000 ^[10]. Many Classic Choice term policies can be converted to permanent coverage without a new medical exam, though conversion options vary by term length and product availability ^[11]. Protective holds A+ (Superior) from AM Best, AA− from S&P, AA− from Fitch, and A1 from Moody's ^[12].

Main limitations. Kidney disease can exclude the applicant from accelerated underwriting ^[7]. No public renal underwriting table or guaranteed offer is available for specific CKD stages. Protective lists kidney dialysis as an uninsurable risk, meaning individuals requiring dialysis will face automatic decline for fully underwritten and simplified issue policies ^[13].

3. Corebridge Financial

Questions This Section Answers

• Is Corebridge Financial or Protective better for Stage 1–3a CKD when flexible term lengths matter?
• Does Corebridge Financial offer guaranteed-issue whole life for Stage 4–5 CKD or dialysis patients?

Verdict. Corebridge Financial is a mixed-to-good fit. It may be worth applying for individually underwritten term coverage if kidney disease is early, stable, and otherwise well controlled, but public Corebridge materials do not disclose kidney-disease-specific underwriting rules, approval odds, ratings, or premiums ^[14]. Guaranteed-issue whole life may provide an alternative for applicants with more serious impairment, but it generally involves limited early benefits, lower coverage, and potentially higher cost.

Why it ranked here. Corebridge earned a best position of 1 from google and kimi. Independent sources rate Corebridge Select-a-Term as the best term life option for CKD, offering 18 flexible term lengths (10–35 years) and competitive rates for stage 1 CKD with demonstrated stability ^[15]. Google's evidence bundle notes Corebridge is recognized as a top term life insurance provider for people with early-to-mid stage chronic kidney disease ^[16].

Best suited for. Applicants with Stage 1–3a CKD or a history of impaired kidney function who are willing to undergo individualized underwriting; applicants seeking flexible term lengths through Select-a-Term; and applicants who have been declined or heavily rated elsewhere and need a final-expense-oriented guaranteed-issue option.

Main strengths for the use case. Select-a-Term offers 18 possible term periods ^[14]. Corebridge describes Agile Underwriting+ as a streamlined process that may avoid an exam, laboratory testing, or attending-physician-statement records for some applications ^[17]. Guaranteed Issue Whole Life has a limited death benefit during the first two policy years; if death occurs then, the benefit is 110% of premiums paid ^[18]. Corebridge maintains an A (Excellent) rating from AM Best ^[19].

Main limitations. No public CKD-stage underwriting guide or disease-specific acceptance criteria was verified ^[20]. Accelerated underwriting is not guaranteed and may be unsuitable for applicants with significant kidney impairment or complex comorbidities. Guaranteed-issue coverage may have limited early death benefits, lower limits, and higher premiums.

4. Gerber Life Insurance

Questions This Section Answers

• Is Gerber Life Insurance worth it for Stage 4–5 CKD or dialysis, and what are its main drawbacks?
• What is the exact death benefit Gerber Life pays if the insured dies from kidney failure within the first two years?

Verdict. Gerber Life Guaranteed Life is a potentially good fallback for a U.S. consumer age 50–80 with stage 4–5 chronic kidney disease or dialysis who cannot qualify for medically underwritten coverage and needs a relatively small final-expense benefit ^[21]. It is not generally the best first option for younger buyers, buyers needing substantial income-replacement coverage, or buyers who may qualify for simplified-issue or fully underwritten insurance with immediate full benefits.

Why it ranked here. Gerber was named by 5 platforms and earned a best position of 5. Independent research confirms guaranteed issue is the standard option for Stage 4–5 CKD and dialysis patients when traditional underwriting becomes unavailable ^[22]. Gerber explicitly states coverage is available "regardless of profession or health" for eligible age groups ^[23].

Best suited for. Applicants age 50–80, or age 50–75 in New York, with severe kidney disease or dialysis who need guaranteed acceptance; final expenses, small debts, or a modest legacy rather than mortgage, income-replacement, or estate-liquidity needs; and buyers who prioritize acceptance certainty and fixed premiums over low cost, high coverage, or immediate full disease-related benefits.

Main strengths for the use case. No health questions, medical exam, or medical records request ^[24]. Guaranteed approval for all applicants age 50–80 (50–75 in New York) who are U.S. citizens or permanent legal residents in covered states ^[25]. Policy provides permanent whole life coverage as long as premiums are paid, and the premium rate never increases. Gerber Life Insurance Company is rated A+ (Superior) by AM Best as of February 2026 ^[26].

Main limitations. For non-accidental deaths within the first 24 months, the beneficiary receives only 110% of premiums paid, not the full death benefit ^[27]. Maximum guaranteed issue coverage is $25,000 total across all Gerber Guaranteed Life policies, with a $15,000 maximum in South Dakota ^[28].

5. Prudential

Questions This Section Answers

• Is Prudential the best carrier for Stage 2 or Stage 3a CKD when the applicant wants fully underwritten term coverage?
• What creatinine level does Prudential use to decline a kidney disease applicant?

Verdict. Prudential is a good fit for consumers with early-to-moderate chronic kidney disease (Stage 2–3a CKD) who can complete full medical underwriting. The company evaluates pre-existing kidney conditions individually rather than automatically declining applicants, offers flexible underwriting for health-impaired applicants, and maintains strong financial stability ^[29]. However, Prudential is not the optimal choice for advanced kidney disease (Stage 4–5), dialysis patients, or those seeking guaranteed issue coverage without medical underwriting.

Why it ranked here. Prudential earned a best position of 1 from anthropic and an average listed position of 2.00 — the best average in the study. Independent sources describe Prudential as relatively flexible for some Stage 2 to Stage 3a CKD cases ^[30]. Google's evidence bundle notes Prudential can offer up to "Preferred Best" health classifications for applicants with kidney issues if their condition is highly stable, serum creatinine is 1.5 mg/dL or less, and urine tests are normal ^[31].

Best suited for. Applicants with stable Stage 2 or Stage 3a CKD seeking fully underwritten term coverage; applicants needing permanent coverage and willing to undergo detailed medical underwriting; and applicants using an independent broker to obtain an informal underwriting assessment before submitting an application.

Main strengths for the use case. Prudential evaluates pre-existing conditions during underwriting rather than automatically disqualifying applicants ^[29]. Offers Level-Premium Term Life in 10-, 15-, 20-, and 30-year terms; Flexible Underwriting Term Life available in 10–40 year terms; and Universal Life products ^[32]. Applicants under 60 may qualify for accelerated underwriting without medical exam up to $3 million ^[32]. Prudential maintains A+ (Superior) financial strength rating from AM Best ^[33]. Prudential utilizes a Rate Reduction Program designed to ease the premium burden on substandard risks ^[34].

Main limitations. No publicly confirmed guaranteed-issue options for applicants unable to undergo medical underwriting ^[35]. Dialysis and end-stage renal disease typically result in automatic decline ^[36].

6. Transamerica

Questions This Section Answers

• Is Transamerica a good choice for final-expense coverage with Stage 1–3 CKD, and what are its coverage limits?
• Does Transamerica accept dialysis patients for its Immediate Solution or only for the graded Easy Solution?

Verdict. Transamerica is a mixed fit. Its simplified-issue final-expense portfolio may be practical for some applicants with chronic kidney disease or impaired kidney function, particularly when modest permanent coverage is the goal and full underwriting is difficult ^[37]. However, the public materials do not establish kidney-disease acceptance criteria, guaranteed eligibility, or likely pricing by CKD stage, eGFR, dialysis status, cause, or comorbidities.

Why it ranked here. Transamerica was named by 3 platforms and earned a best position of 3 from openai. Google's evidence bundle notes that for Transamerica's Final Expense Solutions Portfolio, applicants with mild to moderate CKD (Stages 1–3) or any kidney disorder treatment within 4 years can qualify for Standard rates, granting immediate (first-day) death benefit coverage ^[38]. Patients in Stages 4–5 qualify only for the graded Easy Solution.

Best suited for. Consumers seeking approximately $1,000–$50,000 of permanent final-expense coverage; applicants who may not qualify for preferred traditional underwriting but can answer simplified-issue health questions acceptably; and applicants who value a digital application and potentially rapid underwriting decisions.

Main strengths for the use case. Final Expense Solutions Portfolio covers $1,000–$50,000 for ages 0–85, with a guaranteed level premium regardless of the policyholder's age or health [e6:official:C1]. No medical exam required; underwriting is based solely on health questionnaire responses ^[39]. FE Express Solution offers real-time underwriting with instant decisions and policy delivery in as little as 10 minutes ^[40]. Immediate and 10-Pay solutions include optional accelerated death benefit riders for terminal illness and nursing home care, providing up to 75% of death benefit ^[41].

Main limitations. Applicants on dialysis are likely to be declined; dialysis is typically an automatic decline across the industry and not listed in Transamerica's acceptable conditions ^[42]. Stage 4–5 kidney disease not explicitly listed as acceptable; likely automatic declination for this population. Death benefits are modest ($25,000–$100,000 maximum) compared to traditional life insurance.

7. Lincoln Financial Group

Read the full Lincoln Financial Group fit review for supporting evidence and buying considerations.

Verdict. Lincoln Financial is a mixed fit for Life Insurance for Kidney Disease. It is worth considering for applicants with mild or stable kidney impairment who can qualify through conventional underwriting, especially when TermAccel's coverage limits and conversion feature match the need ^[43]. It is not demonstrably kidney-disease-specialized from public evidence, and its TermAccel marketing emphasis on good health makes it uncertain for moderate or advanced CKD.

Why it ranked here. Lincoln was named by 2 platforms (google, perplexity) and earned a best position of 3 from both. Google's evidence bundle notes Lincoln is considered a strong target carrier for applicants with stable, mild-to-moderate proteinuria combined with a normal eGFR (>60), utilizing a risk-stratified underwriting approach that evaluates long-term stability ^[44]. Lincoln TermAccel offers 10-, 15-, 20-, and 30-year level-premium periods, a $100,000 minimum face amount, and a $2.5 million maximum face amount ^[43].

Best suited for. Applicants with mild or stable kidney impairment, adequate documentation, and a need for conventional term coverage; applicants seeking $100,000 to $2.5 million of TermAccel coverage and who may qualify for Lincoln's underwriting classes; and applicants with permanent insurance, cash-value, or estate-planning objectives who understand VUL investment risk and ongoing policy expenses.

Main strengths for the use case. Lincoln LifeElements Level Term is designed for high-risk applicants and complex medical histories, offering flexible underwriting that may accommodate kidney disease applicants who do not qualify for TermAccel ^[45]. Universal life products (UL, IUL, VUL) offer customizable coverage with cash value accumulation and flexible underwriting suitable for long-term kidney disease management ^[46]. Chronic Illness accelerated death benefit rider allows early access to policy funds during progression of kidney disease ^[47]. No-lapse guarantee riders on universal life policies protect against policy lapse ^[48].

Main limitations. Lincoln TermAccel explicitly lists chronic kidney failure as a disqualifying condition ^[49]. MoneyGuard (hybrid life/long-term care) product lists dialysis/kidney failure as uninsurable ^[50].

8. John Hancock

Questions This Section Answers

• Is John Hancock worth it for Stage 2–3a CKD, and how much can the Vitality program reduce premiums?
• Does John Hancock's Simple Term with Vitality accept applicants with kidney disease?

Verdict. John Hancock is a potentially reasonable candidate for a consumer with stable, early-stage kidney disease, particularly Stage 2 or Stage 3a, but it is not demonstrably a kidney-disease specialist ^[51]. The main decision will be individualized medical underwriting, and John Hancock does not publicly disclose a kidney-specific acceptance or pricing guide sufficient to predict approval or premiums.

Why it ranked here. John Hancock was named by 2 platforms (anthropic, kimi) and earned a best position of 2 from anthropic. Independent source reports John Hancock considers Stage 3a applicants with stable labs and strong A1C control, offering table ratings where competitors may decline ^[52]. John Hancock's underwriting guide explicitly evaluates renal function using BUN and serum creatinine levels, requiring Attending Physician Statement for abnormal findings ^[53].

Best suited for. Applicants with stable Stage 2 or Stage 3a CKD who can qualify through fully underwritten term or permanent life insurance; applicants who value wellness rewards and may use Vitality participation to reduce eligible premiums; and applicants needing conventional term coverage, including stated company ranges of 10–30 years and $250,000–$30 million, subject to underwriting and state availability ^[51].

Main strengths for the use case. John Hancock's underwriting guide explicitly evaluates renal function using BUN and serum creatinine levels, with clear approval pathways for Stage 2–3a CKD with stable metrics and controlled comorbidities ^[53]. Vitality wellness program integrated with life insurance, offering 15–25% premium discounts for compliant participants ^[54]. Separate Aspire program for diabetics with virtual clinic support (Onduo), addressing common comorbidity with CKD ^[55]. Multiple product types (Term, UL, Survivorship) providing flexibility for different financial and estate planning needs ^[51].

Main limitations. John Hancock's underwriting guide says kidney disease or failure is not eligible for Simple Term with Vitality ^[56]. Application process typically takes 6–10 weeks (vs. 3–4 weeks standard), primarily due to APS retrieval delays from nephrologists ^[57].

9. Banner Life

Questions This Section Answers

• Is Banner Life a good choice for Stage 2 CKD when the applicant wants competitive term rates?
• Does Banner Life's accelerated underwriting accept applicants with chronic kidney disease?

Verdict. Banner Life OPTerm may be a reasonable candidate for a consumer with mild, stable kidney impairment, particularly Stage 2 CKD, but it is not demonstrably kidney-disease-specialized ^[58]. Public materials do not provide a Banner-specific CKD acceptance table or guaranteed rating. Suitability depends on individualized underwriting of kidney function, cause, progression, treatment, blood pressure, diabetes, and other health factors.

Why it ranked here. Banner was named by 2 platforms (anthropic, kimi) and earned a best position of 4 from anthropic. Kimi notes Banner Life (Legal & General America) is noted for competitive table-rated term pricing specifically for Stage 2 CKD applicants, where competitors may offer less favorable ratings ^[59]. Google's evidence bundle notes Banner Life provides highly competitive base premiums for its OPTerm policies, and substandard rates are uniquely calculated using the "Standard Plus" tier as the baseline rather than "Standard," rendering the extra fees lower than many industry peers ^[60].

Best suited for. Applicants with early-stage or stable kidney impairment who want medically underwritten term coverage; applicants seeking level-premium term coverage for 10–40 years with conversion and renewal features; and applicants willing to use an independent impaired-risk broker to compare Banner with other carriers before submitting a formal application.

Main strengths for the use case. OPTerm offers 10, 15, 20, 25, 30, 35, and 40-year terms, subject to eligibility ^[58]. Banner's product specifications indicate that substandard classes may be available through Table 12, subject to underwriting discretion, with premiums increased by 25% per table rating for the stated non-tobacco structure ^[61]. Banner's use of "standard plus" rate class when pricing health impairments gives it an advantage ^[62]. Banner underwrites individuals, not impairments, using a holistic approach that reviews the entirety of the risk ^[63]. Banner's consumer product material identifies AM Best A+ and Standard & Poor's AA- ratings ^[64].

Main limitations. No public Banner-specific CKD underwriting chart or published Stage 2 CKD rate class was located ^[58].

10. Colonial Penn

Questions This Section Answers

• Is Colonial Penn worth it for Stage 4–5 CKD or dialysis, and what are its main drawbacks?
• What is the exact death benefit Colonial Penn pays if the insured dies from kidney failure within the first two years?

Verdict. Colonial Penn is a good, but narrow, fit for Life Insurance for Kidney Disease when guaranteed acceptance and modest permanent final-expense coverage are the priorities ^[65]. Its main advantages are acceptance without health questions or an exam and a stated level premium. Its main disadvantages are the two-year limited-benefit period, potentially limited coverage amount, and unclear value per dollar without a personalized quote.

Why it ranked here. Colonial Penn was named by 2 platforms (anthropic, perplexity) and earned a best position of 6 from perplexity. Colonial Penn states that acceptance is guaranteed regardless of pre-existing conditions, with no health questions and no medical exam ^[65]. This directly addresses applicants with severe CKD or dialysis, although the policy remains subject to its limited early-benefit provisions.

Best suited for. Applicants with severe CKD, kidney failure, dialysis, or multiple health conditions who need acceptance regardless of health; consumers seeking relatively small permanent coverage for funeral, burial, debt, or final medical expenses; and applicants who prefer no medical exam and no health questions.

Main strengths for the use case. Guaranteed acceptance can make coverage available despite stage 4–5 CKD, dialysis, or other serious comorbidities ^[65]. No medical exam or health questions reduce application friction and eliminate ordinary medical underwriting. Permanent coverage with a stated locked-in premium may be useful for predictable final-expense planning ^[66]. Health deterioration after issue is not stated to reduce the benefit, provided the policy remains active. Colonial Penn is rated A (Excellent) by AM Best ^[67].

Main limitations. The two-year limited-benefit period is material for applicants with advanced kidney disease and must be understood before purchase ^[68]. If the insured person dies from natural causes within the first two years of the policy, Colonial Penn does NOT pay the full death benefit; instead, beneficiaries receive a refund of all premiums paid, plus 7% annual interest ^[69].

What the Cross-Platform Study Reveals About This Market

Questions This Section Answers

• What do AI platforms agree on about life insurance for kidney disease, and where do they disagree?
• How should a buyer with kidney disease use AI platform recommendations when choosing a carrier?

The cross-platform study reveals a market segmented by CKD stage rather than by carrier reputation. Every platform that named Mutual of Omaha placed it in the top five, and its guaranteed-issue and simplified-issue products were consistently described as the most accessible path for advanced disease. Protective, Corebridge Financial, and Prudential clustered as the leading fully underwritten options for stable early-stage CKD, with Prudential earning the best average listed position (2.00) despite being named by only 4 platforms. Gerber Life Insurance and Colonial Penn anchored the guaranteed-issue fallback tier, with Gerber named by 5 platforms and Colonial Penn by 2.

The study also reveals a persistent evidence gap: no platform located a publicly available, kidney-stage-specific underwriting grid for any carrier. Every carrier's fit assessment relied on a combination of company product pages, producer guides, independent broker reviews, and general industry underwriting patterns.

Where the AI Platforms Agreed

Questions This Section Answers

• Which life insurance carriers do all AI platforms recommend for kidney disease?
• What underwriting factors do AI platforms agree matter most for kidney disease life insurance?

All 7 platforms agreed that Mutual of Omaha is a leading option for kidney disease life insurance, and 5 of 7 named Protective, Corebridge Financial, and Gerber Life Insurance. The platforms consistently identified the same underwriting factors as material: CKD stage or severity, eGFR, creatinine, proteinuria or albuminuria, cause of kidney disease, treatment, progression, blood pressure, diabetes, and overall health ^[71].

Platforms also agreed on the structural tradeoffs. Guaranteed-issue whole life was consistently described as the fallback for advanced CKD or dialysis, with a two-year graded benefit period and limited face amounts ^[71]. Fully underwritten term was consistently described as the preferred path for stable early-stage CKD, with table ratings (typically 25% per table) as the expected pricing mechanism for impaired risk ^[76]. .

Where the AI Platforms Disagreed

Questions This Section Answers

• Why do AI platforms disagree about which carrier is best for kidney disease life insurance?
• Which carrier's kidney disease fit rating varied most across AI platforms?

Platforms disagreed most sharply on fit ratings for individual carriers. Mutual of Omaha received fit ratings ranging from "strong" (kimi) to "mixed" (grok, perplexity). Kimi rated it "strong" for Stage 3b–5 and dialysis patients ^[79], while grok reported that dialysis or ESRD typically declines Living Promise Level/Graded ^[80]. Perplexity found that publicly available sources do not clearly verify a kidney-disease-specific approval rule, stage-based chart, or guaranteed acceptance for CKD or dialysis ^[81].

Corebridge Financial received fit ratings ranging from "strong" (google) to "mixed" (deepseek, openai, perplexity). Google rated it "strong" and noted it offers both term and guaranteed-issue paths ^[82], while deepseek found the ranking-stage product mapping unverified and noted no public CKD-specific underwriting guidelines on Corebridge's site ^[83].

Prudential received fit ratings ranging from "good" (anthropic, google, kimi) to "mixed" (grok, openai, perplexity) to "uncertain" (deepseek).

How Buyers Should Choose

Questions This Section Answers

• What should a buyer with kidney disease check before choosing a life insurance carrier?
• How can a buyer with kidney disease compare guaranteed-issue and fully underwritten life insurance options?

Buyers should choose based on CKD stage, documentation quality, and coverage goal rather than carrier reputation alone. The following decision sequence reflects the cross-platform evidence:

1. Determine CKD stage and current kidney function. Stage 1–2 CKD with stable eGFR >60 and controlled blood pressure may qualify for standard or mildly substandard rates at fully underwritten carriers ^[84]. Stage 3a may qualify for table ratings at carriers with renal underwriting experience ^[86]. Stage 3b–5 or dialysis typically requires guaranteed-issue or simplified-issue coverage ^[88].

2. Assess documentation quality. Carriers evaluate stability and progression, not just current stage. At least 12 months of stable kidney function labs is a common threshold for moving applicants from declined to table-rated ^[90]. An Attending Physician Statement from a nephrologist is commonly required ^[91].

Methodology

This study used one standardized prompt sent once to each of 7 included platforms: openai, anthropic, deepseek, grok, perplexity, kimi, and google. The prompt asked which life insurance carriers are generally worth considering for applicants with kidney disease, and why. The research date was 2026-09-22.

Platforms were included based on the configured platform list. Each platform's response was parsed for named entities. An entity qualified for the final ranking only if it was named by at least two platforms during ranking discovery. The final ranking order is based on platform mentions, then average listed rank, then best listed rank. Platform mentions count only ranking-discovery mentions; all included platforms evaluated fit, but not every platform named every carrier.

Entity evidence bundles were compiled from platform-reported claims, citations, and source support. Citations are platform-reported evidence, not independently verified facts. The URLs were collected from platform responses and were not independently validated by the writer stage. Company-owned sources are distinguished from independent sources where the evidence bundles provide that information.

Methodology Limitations

AI answers can vary by date, wording, location, account state, model, interface, browsing configuration, and the sources retrieved. This study used one standardized prompt sent once to each platform, so results reflect a single snapshot rather than repeated testing.

Platform-reported research dates differ from the authoritative run date. Deepseek reported a research date of 2026-06-01 for Mutual of Omaha, 2026-01-15 for Protective, 2026-06-01 for Corebridge Financial, 2026-05-20 for Gerber Life Insurance, 2026-06-01 for Prudential, 2026-06-11 for Colonial Penn, 2026-01-15 for Lincoln Financial Group, 2026-01-15 for John Hancock, and 2026-01-15 for Banner Life. These dates are provenance metadata and do not independently prove freshness.

No platform published a kidney-stage-specific underwriting grid for every carrier. Fit assessments relied on a combination of company product pages, producer guides, independent broker reviews, and general industry underwriting patterns. Some platforms reported conflicting product names, pricing, or capabilities; these conflicts are described in the individual ranked sections rather than resolved by guessing.

The deterministic identity audit contains qualification notes that must be disclosed where relevant.

Final Verdict

Mutual of Omaha is the consensus leader for life insurance with kidney disease, named by all 7 platforms and ranked first overall. It is the strongest fit for applicants with advanced, unstable, or poorly documented kidney disease who need guaranteed-issue or simplified-issue final-expense coverage. Protective and Corebridge Financial are the strongest alternatives for stable, well-documented kidney impairment requiring fully underwritten term coverage, with Prudential offering the best average listed position among fully underwritten carriers. Gerber Life Insurance and Colonial Penn are the fallback options for severe kidney disease or dialysis, with Gerber named by 5 platforms and Colonial Penn by 2.

The study's principal limitation is that no platform published a kidney-stage-specific underwriting grid for every carrier, and AI answers can vary by date, wording, location, account state, model, interface, browsing configuration, and the sources retrieved. Buyers should use this index as a starting point for carrier comparison, not as a substitute for a case-specific quote or informal underwriting assessment.